Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CLAUDIA T MARTORELL

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1609834662
CMS profile
162969
Location
SPRINGFIELD, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$165,204.99

181 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ViiV Healthcare Company $89,971.97 93
Gilead Sciences, Inc. $54,569.95 66
Theratechnologies Inc. $20,562.06 21
PFIZER INC. $101.01 1

Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CLAUDIA T MARTORELL

NPI 1609834662 · CMS profile ID 162969

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

SPRINGFIELD, MA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1609834662?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CLAUDIA T MARTORELL, NPI 1609834662, CMS profile ID 162969. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1609834662?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). CLAUDIA T MARTORELL, NPI 1609834662, CMS profile ID 162969. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1609834662?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
CLAUDIA T MARTORELL, NPI 1609834662, CMS profile ID 162969, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1609834662?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

181 matching records · $165,204.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 181 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 181.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Theratechnologies Inc. $47.0205/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226365665 CMS
ViiV Healthcare Company $430.6105/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189545411 CMS
ViiV Healthcare Company $31.4105/09/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189569267 CMS
ViiV Healthcare Company $1,300.0005/05/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189546453 CMS
Theratechnologies Inc. $500.0005/01/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1226365775 CMS
ViiV Healthcare Company $1,355.6005/01/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189563394 CMS
ViiV Healthcare Company $89.3005/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189597296 CMS
ViiV Healthcare Company $2,600.0004/29/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189543613 CMS
Gilead Sciences, Inc. $2,760.0004/28/2025 Consulting Fee No dispute reported Delay: No
Change: NEW
06/30/2026 1234351516 CMS
Gilead Sciences, Inc. $6,490.0004/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234353403 CMS
ViiV Healthcare Company $337.9804/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189521642 CMS
Gilead Sciences, Inc. $2,900.0004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234355984 CMS
ViiV Healthcare Company $2,600.0004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189540551 CMS
ViiV Healthcare Company $2,600.0004/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189564226 CMS
Gilead Sciences, Inc. $17.6404/18/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234374213 CMS
Gilead Sciences, Inc. $135.0004/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234378626 CMS
Gilead Sciences, Inc. $8.5804/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234590314 CMS
Gilead Sciences, Inc. $243.3904/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234369264 CMS
Gilead Sciences, Inc. $30.0004/10/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234373555 CMS
Gilead Sciences, Inc. $60.0004/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234410506 CMS
Gilead Sciences, Inc. $149.8404/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234375716 CMS
ViiV Healthcare Company $2,600.0004/07/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189579972 CMS
ViiV Healthcare Company $2,600.0004/03/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189550383 CMS
ViiV Healthcare Company $89.6804/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189609791 CMS
ViiV Healthcare Company $7,150.0003/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189519630 CMS
ViiV Healthcare Company $1,625.0003/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189530856 CMS
ViiV Healthcare Company $131.6003/28/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189585895 CMS
ViiV Healthcare Company $124.9003/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189511150 CMS
ViiV Healthcare Company $1,542.5603/27/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189567727 CMS
Theratechnologies Inc. $120.0003/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226365711 CMS
Theratechnologies Inc. $2,500.0003/26/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1226365717 CMS
ViiV Healthcare Company $5.0003/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189523132 CMS
ViiV Healthcare Company $225.9303/25/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189626689 CMS
Gilead Sciences, Inc. $28.0003/20/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1234373693 CMS
Gilead Sciences, Inc. $15.9303/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234566022 CMS
Gilead Sciences, Inc. $8.7003/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234589914 CMS
Theratechnologies Inc. $120.0003/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1226365700 CMS
Theratechnologies Inc. $2,000.0003/18/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1226365705 CMS
ViiV Healthcare Company $20.3803/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189561688 CMS
ViiV Healthcare Company $29.4003/14/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189608673 CMS
Gilead Sciences, Inc. $3,240.0003/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234355210 CMS
Gilead Sciences, Inc. $1,870.0003/13/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1234357927 CMS
ViiV Healthcare Company $111.0303/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189511336 CMS
ViiV Healthcare Company $1,284.9603/12/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1189588309 CMS
Gilead Sciences, Inc. $7.9303/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234592188 CMS
ViiV Healthcare Company $3.9703/06/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189604521 CMS
Theratechnologies Inc. $2,500.0003/05/2025 Honoraria No dispute reported Delay: No
Change: NEW
06/30/2026 1226365695 CMS
ViiV Healthcare Company $2,600.0003/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189545863 CMS
ViiV Healthcare Company $2,600.0003/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1189554032 CMS
ViiV Healthcare Company $113.6903/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1189528584 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $199,560.84 215
PY2020 $81,111.98 81
PY2021 $52,807.96 59
PY2022 $92,003.93 113
PY2023 $185,727.21 214
PY2024 $213,984.70 205
PY2025 $165,204.99 181

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $744,158.52 59
PY2024 Principal investigator $359,587.03 26
PY2023 Recipient $2,580.45 22
PY2023 Principal investigator $30,412.46 6
PY2022 Principal investigator $44,302.88 7
PY2021 Principal investigator $40,466.58 22
PY2020 Principal investigator $83,229.82 34
PY2019 Recipient $1,738.37 18
PY2019 Principal investigator $121,927.03 40

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SANOFI PASTEUR INC. $3,680.00 12/30/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226105002
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228722614
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228723444
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725594
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725672
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228725756
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732209
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732221
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228732832
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733065
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733385
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228733837
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734148
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734151
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734154
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734503
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228734764
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735109
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228735113
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228738969
Principal investigator 1 PFIZER INC. $426.60 12/08/2025 Non-covered Recipient Entity
Walgreens Clinical Trials Malden MA
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228738972
Principal investigator 1 SANOFI PASTEUR INC. $4,680.00 11/20/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226105012
Principal investigator 1 ViiV Healthcare Company $15,549.53 11/19/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL MD-INFECTIOUS DISEASES & HIV
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318679
Principal investigator 1 ABBVIE INC. $3,696.90 11/04/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202520983
Principal investigator 1 ViiV Healthcare Company $11,396.07 10/28/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318609
Principal investigator 1 SANOFI PASTEUR INC. $33,120.00 10/24/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226105019
Principal investigator 1 SANOFI PASTEUR INC. $2,187.50 10/24/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226105024
Principal investigator 1 SANOFI PASTEUR INC. $3,680.00 10/24/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226105032
Principal investigator 1 ABBVIE INC. $830.04 10/09/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202516135
Principal investigator 1 SANOFI PASTEUR INC. $27,747.20 10/01/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226105006
Principal investigator 1 ViiV Healthcare Company $8,450.04 09/19/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318417
Principal investigator 1 ViiV Healthcare Company $19,341.74 09/17/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318421
Principal investigator 1 ABBVIE INC. $4,891.24 09/03/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202508228
Principal investigator 1 ViiV Healthcare Company $10,786.82 08/29/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318413
Principal investigator 1 ViiV Healthcare Company $14,014.81 08/21/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL MD-INFECTIOUS DISEASES & HIV
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318677
Principal investigator 1 ABBVIE INC. $4,918.54 08/05/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202502166
Principal investigator 1 Theratechnologies Inc. $2,008.50 08/04/2025 Non-covered Recipient Entity
Infectious Disease and The Research Institute
A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States (PROMISE-US) No dispute reported 06/30/2026 1249666487
Principal investigator 1 ViiV Healthcare Company $14,151.74 07/23/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318615
Principal investigator 1 ViiV Healthcare Company $18,021.59 07/21/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318409
Principal investigator 1 ABBVIE INC. $1,935.68 07/02/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202496565
Principal investigator 1 ViiV Healthcare Company $5,861.70 06/22/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318619
Principal investigator 1 ViiV Healthcare Company $7,178.89 06/12/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318605
Principal investigator 1 ViiV Healthcare Company $24,198.56 06/12/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318617
Principal investigator 1 ViiV Healthcare Company $14,646.06 06/11/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318613
Principal investigator 1 ViiV Healthcare Company $31,047.98 06/10/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190318419
Principal investigator 1 ABBVIE INC. $6,070.98 06/03/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202488139
Principal investigator 1 SANOFI PASTEUR INC. $24,752.00 05/22/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226104996
Principal investigator 1 ViiV Healthcare Company $12,182.34 05/16/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318415
Principal investigator 1 ABBVIE INC. $8,766.18 05/07/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202483055
Principal investigator 1 ViiV Healthcare Company $8,497.71 04/28/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318611
Principal investigator 1 SANOFI PASTEUR INC. $42,598.40 04/21/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226104987
Principal investigator 1 ABBVIE INC. $6,373.54 04/03/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202473963
Principal investigator 1 ViiV Healthcare Company $9,899.96 03/21/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318411
Principal investigator 1 SANOFI PASTEUR INC. $199,035.20 03/20/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226104980
Principal investigator 1 SANOFI PASTEUR INC. $92,664.00 03/19/2025 Non-covered Recipient Entity
Walgreens Pharmacy 06489
A Phase 1/2, Parallel, Randomized, Modified Double-blind, Multi-arm Study to Assess the Safety and Immunogenicity of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and Recombinant Influenza Vaccine in Adult Participants 50 Years of Age and Older No dispute reported 06/30/2026 1226104972
Principal investigator 1 ABBVIE INC. $6,081.02 03/07/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202459604
Principal investigator 1 ViiV Healthcare Company $12,211.59 02/24/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318681
Principal investigator 1 ABBVIE INC. $7,917.60 02/06/2025 Non-covered Recipient Entity
CLAUDIA MARTORELL
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202449365
Principal investigator 1 ViiV Healthcare Company $10,554.87 01/28/2025 Non-covered Recipient Entity
MARTORELL CLAUDIA T MD LLC
A PHASE 2B MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY COMPARING THE EFF No dispute reported 06/30/2026 1190318607